BIO KEY INTERNATIONAL INC, trading under the ticker BKYI on the OTC market, is a prepackaged software services provider with a market capitalization of approximately 4.32 million dollars and 1.09 million shares outstanding. Recent regulatory filings indicate that the company is navigating operational and reporting challenges that retail investors should monitor closely. These challenges are highlighted by a series of SEC filings related to disclosure delays and compliance issues.
On May 18, 2026, the company filed a Form NT 10-Q, which is a notification of late filing, indicating that it could not timely file its quarterly report for the period ending March 31, 2026. On the same day, the company filed a Form 8-K under Item 2.02 to release its financial results. Delays in filing periodic reports can limit the visibility that investors have into a company's current financial health and can sometimes signal underlying accounting or administrative constraints.
Following this reporting delay, BIO KEY INTERNATIONAL INC filed two separate Form 8-K documents under Item 3.01, which denotes a notice of delisting or failure to satisfy a continued listing rule or standard. These filings were dated May 12, 2026, and June 10, 2026. While the specific details of the compliance failures are not elaborated in the basic data, Item 3.01 filings generally represent a heightened risk regarding the company's regulatory standing and its ability to maintain standard trading privileges.
Additionally, the company filed a Form 8-K on April 29, 2026, covering Items 3.03 and 5.03, which relate to material modifications to the rights of security holders and amendments to the articles of incorporation. These corporate actions, combined with a shareholder meeting report on Form 8-K filed on April 24, 2026, suggest ongoing structural adjustments. Investors should remain cautious, as late filings and regulatory notices are significant risk factors that can impact liquidity and reporting transparency.